Leading mRNA sciences.
The BASE facility is located in the Australian Institute of Bioengineering and Nanotechnology (AIBN) at the University of Queensland, and hosts state-of-the-art equipment and bioprocessing technologies, with a team of skilled and experienced scientists to provide mRNA services.
We are a joint initiative supported by Protein Expression Facility (PEF), National Biologics Facility (NBF) and Therapeutics Innovation Australia (TIA).
The BASE facility makes mRNA vaccines and therapies for Australian researchers. We can help with project and mRNA design, small to large scale manufacture, formulation and expression validation. All research services are supported by rigorous quality control.
mRNA vaccines and therapies are being developed to treat many diseases. The BASE facility, in partnership with PEF and NBF, supports the manufacture of mRNA for translational use, including pre-clinical and early clinical leads.
mRNA can also be used for many applications, including modulating gene expression, editing the genome, and re-programming and engineering cells. We also provide a wide range of mRNA reagents for use in research applications.
The BASE team leverages our unique manufacturing capabilities to drive mRNA research. We focus on early-stage technologies with commercial outcomes. We are developing new mRNA platform technologies, optimising manufacturing processes (including enzymatic DNA synthesis and enzyme engineering), and innovative clinical, industrial and agricultural applications.
Our leading research is recognised by international industry partners whoclosely with BASE to develop new mRNA technologies, optimise manufacturing processes and build mRNA prototypes according to specification.